XML 99 R68.htm IDEA: XBRL DOCUMENT v3.21.2
Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) $ (502.9) $ (128.6) $ (913.4) $ (186.1)
Income Tax Expense (Benefit) (25.9) 240.8 (390.7) 979.0
Product revenues 2,778.9 3,376.1 8,247.9 10,592.0
Net income attributable to Biogen Inc. 329.2 701.5 1,187.9 3,642.7
Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Net income attributable to Biogen Inc. (14.0) (6.6) (63.0) 35.9
Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) (0.4) 0.1 (1.3) (12.4)
Income Tax Expense (Benefit) 0.1 0.0 0.3 2.6
Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) 0.0 0.0 0.1 0.2
Income Tax Expense (Benefit) 1.5 0.1 6.8 (0.1)
Product revenues (14.9) (9.1) (68.7) 41.6
Operating Expenses (0.3) 1.5 (0.3) 1.4
Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]        
Nonoperating Income (Expense) $ 0.0 $ 0.8 $ 0.1 $ 2.6